JP2016512817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512817A5 JP2016512817A5 JP2016500694A JP2016500694A JP2016512817A5 JP 2016512817 A5 JP2016512817 A5 JP 2016512817A5 JP 2016500694 A JP2016500694 A JP 2016500694A JP 2016500694 A JP2016500694 A JP 2016500694A JP 2016512817 A5 JP2016512817 A5 JP 2016512817A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- canagliflozin
- probenecid
- amount ranging
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960001713 canagliflozin Drugs 0.000 claims description 24
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims description 16
- 229960003081 probenecid Drugs 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 201000005569 Gout Diseases 0.000 claims description 8
- 201000001431 Hyperuricemia Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000000913 Kidney Calculi Diseases 0.000 claims description 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 230000006978 adaptation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786738P | 2013-03-15 | 2013-03-15 | |
| US61/786,738 | 2013-03-15 | ||
| PCT/US2014/020958 WO2014149789A1 (en) | 2013-03-15 | 2014-03-06 | Combination of canagliflozin and probenecid for the treament of hyperuricemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019022272A Division JP2019089825A (ja) | 2013-03-15 | 2019-02-12 | 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512817A JP2016512817A (ja) | 2016-05-09 |
| JP2016512817A5 true JP2016512817A5 (enExample) | 2017-04-06 |
Family
ID=50483479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500694A Withdrawn JP2016512817A (ja) | 2013-03-15 | 2014-03-06 | 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ |
| JP2019022272A Pending JP2019089825A (ja) | 2013-03-15 | 2019-02-12 | 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019022272A Pending JP2019089825A (ja) | 2013-03-15 | 2019-02-12 | 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20160022632A1 (enExample) |
| EP (1) | EP2968235B1 (enExample) |
| JP (2) | JP2016512817A (enExample) |
| CA (1) | CA2907079C (enExample) |
| ES (1) | ES2647526T3 (enExample) |
| WO (1) | WO2014149789A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105548378B (zh) * | 2015-12-03 | 2017-12-26 | 上海应用技术学院 | 一种卡格列净α、β异构体的分离方法 |
| WO2019087239A1 (ja) * | 2017-10-30 | 2019-05-09 | 合同会社カルナヘルスサポート | 腎症治療剤 |
| US11547685B2 (en) * | 2017-12-11 | 2023-01-10 | Mayo Foundation For Medical Education And Research | Using probenecid to treat polycystic kidney disease |
| US11554112B2 (en) | 2018-06-07 | 2023-01-17 | Herum Therapeutics International Limited | Combinations of β-lactam compounds and probenecid and uses thereof |
| AU2019392750B2 (en) | 2018-12-06 | 2025-07-10 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| BR112021010708A2 (pt) | 2018-12-06 | 2021-08-24 | Arthrosi Therapeutics, Inc. | Formas cristalinas de um composto para tratar ou prevenir gota ou hiperuricemia |
| US20200253878A1 (en) | 2019-02-13 | 2020-08-13 | Iterum Therapeutics International Limited | Combinations of beta-lactam compounds and probenecid and uses thereof |
| CN111057049B (zh) * | 2019-11-18 | 2021-06-01 | 杭州华东医药集团新药研究院有限公司 | 一种卡格列净半水化合物的制备方法 |
| EP4164624A4 (en) * | 2020-06-10 | 2024-10-16 | Arthrosi Therapeutics, Inc. | METHODS OF TREATMENT OR PREVENTION OF CHRONIC KIDNEY DISEASE |
| CN112957318A (zh) * | 2021-02-02 | 2021-06-15 | 河北科星药业有限公司 | 丙磺舒溶液及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2896397T (lt) | 2003-08-01 | 2017-11-27 | Mitsubishi Tanabe Pharma Corporation | Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| BRPI0913129A2 (pt) * | 2008-05-22 | 2016-01-05 | Bristol Myers Squibb Co | método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo |
| JP2013523681A (ja) * | 2010-03-30 | 2013-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用 |
-
2014
- 2014-03-06 WO PCT/US2014/020958 patent/WO2014149789A1/en not_active Ceased
- 2014-03-06 CA CA2907079A patent/CA2907079C/en active Active
- 2014-03-06 EP EP14717246.4A patent/EP2968235B1/en active Active
- 2014-03-06 JP JP2016500694A patent/JP2016512817A/ja not_active Withdrawn
- 2014-03-06 US US14/774,779 patent/US20160022632A1/en not_active Abandoned
- 2014-03-06 ES ES14717246.4T patent/ES2647526T3/es active Active
-
2017
- 2017-09-07 US US15/698,062 patent/US20170368025A1/en not_active Abandoned
-
2019
- 2019-02-12 JP JP2019022272A patent/JP2019089825A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512817A5 (enExample) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| MD4539B1 (ro) | 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1 | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| EA201170018A1 (ru) | Разагилин для изменения течения болезни паркинсона | |
| JP2010222367A5 (enExample) | ||
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2016518337A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2017075173A5 (enExample) | ||
| WO2005097125A3 (en) | Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease | |
| CO6612185A2 (es) | Composiciones famacéuticas para el tratamiento del cáncer y otras enfermedades o transtornos | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2011522816A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| WO2010144336A3 (en) | Methods for treating chronic kidney disease | |
| JP2017501848A5 (enExample) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2017526695A5 (enExample) | ||
| JP2015537009A5 (enExample) | ||
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| JP2016519107A5 (enExample) | ||
| EA201990664A1 (ru) | Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма | |
| JP2016527312A5 (ja) | ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物 |